[ad_1]
The American pharmaceutical company Moderna announced on Thursday that it had completed the registration process for a possible vaccine against covid-19 in the final phase (phase 3) of clinical trials, for which 30,000 participants are registered.
The clinical trial, to be conducted, will be conducted with volunteers in the United States, including more than 11,000 minority communities (comprising 6,000 Hispanics / Latin Americans and more than 3,000 Black / African Americans), more than 7,000 seniors, and more than 5,000 chronic patients (diabetic, obese and cardiac).
Phase 3, which precedes the application for marketing authorization for a drug, was designed to “assess participants at increased risk for severe COVID-19 disease” but also to test an inclusive vaccine, spanning “communities that historically they have been underrepresented in clinical research and are disproportionately affected “by covid-19, Moderna justifies in a statement.
[ad_2]
